2018 Clinical Trials Events Treatment 
FloridaMarijuana.net
AUGUST 15, 2018
Evidence-based Complementary and Alternative Medicine published an article titled “Post-Traumatic Stress Disorder: Evidence-Based Research for the Third Millennium” which describes how profound the symptoms of PTSD can be: “Traumatic events are profoundly stressful. Women tend to experience different traumas than men.
Cannabis Law Report
AUGUST 10, 2021
This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. The global chronic pain treatment market is predicted to progress at a CAGR of 6.5% from 2020 to 2030 and generate revenue of $151.7
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Cannigma
MAY 19, 2021
While many countries around the world have legalized or decriminalized cannabis or have eased up on enforcement in recent years, in Japan in 2018 there was a sharp increase in cannabis-related arrests — and 80% of them were possession charges. of Japanese have reported consuming cannabis, as opposed to more than 40% in the US and Canada.
The Joint Blog
APRIL 17, 2020
This study summarizes potential adverse drug events related to THC when combined with other medications Medicinal Use of Marijuana Cannabis has been used widely across North America in various state or provincial medical marijuana programs. In 2018, ProCon.org has estimated well over 3.5M
Veriheal
JULY 12, 2021
According to the American Psychiatric Association , PTSD is a “psychiatric disorder that may occur in people who have experienced or witnessed a traumatic event such as natural disaster, as a serious accident, a terrorist act, war/combat or rape or who have been threatened with death, sexual violence or serious injury”.
Cannabis Law Report
JULY 1, 2021
Clinical trials repeatedly demonstrate their promise for treating mood, anxiety, and substance use disorders. In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency identified psilocybin as a breakthrough for treatment-resistant depression.
Cannabis Law Report
MARCH 2, 2020
In 2018, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) to Compass Pathways ‘ psilocybin therapy for treatment-resistant depression. This renewed interest in psychedelics is being sparked by a pair of seemingly unrelated events. Then, something strange happened.
Expert insights. Personalized for you.
182 
Let's personalize your content